Nitrosamine Risk Assessment Services for Drug Products
Systematic evaluation of nitrosamine risk sources, data gaps, and regulatory compliance strategy for MENA and GCC pharmaceutical submissions.
Start Nitrosamine Risk AssessmentWhat is nitrosamine risk assessment for drug products?
Nitrosamine risk assessment evaluates whether a drug product may form or contain nitrosamine impurities through API chemistry, excipients, packaging, manufacturing conditions, storage, or degradation pathways. It identifies risk sources, required testing, mitigation actions, and regulatory documentation needed for compliance with health authority expectations.
Why Nitrosamine Risk Matters
Regulatory authorities globally now require pharmaceutical companies to systematically assess and address nitrosamine risk across their product portfolios.
Regulatory Compliance
ICH M7, WHO guidelines, and MENA/GCC authority requirements mandate systematic nitrosamine risk evaluation for all drug products.
Batch Release Risk
Products failing nitrosamine specifications face batch rejection, market withdrawal, and significant financial and reputational impact.
Product Registration Risk
Incomplete or absent nitrosamine risk assessment documentation is a major cause of CTD deficiency notices from regulators.
Supplier & Excipient Variability
API and excipient sources vary in nitrite content. A single supplier change can introduce new nitrosamine formation risk.
Packaging & Degradation Risk
Primary packaging materials and storage conditions can accelerate nitrosamine formation through chemical interactions.
Understanding Risk Levels
Risk categorization determines the scope of testing, documentation, and mitigation strategy required.
Low Risk
API with no secondary/tertiary amine, low-nitrite excipients, inert packaging, controlled manufacturing process, all data available.
Medium Risk
Moderate amine risk in API, excipient nitrite data partial or absent, packaging materials not fully characterized, or data gaps exist.
High Risk
API with known high amine risk, multiple nitrite-containing excipients, uncharacterized packaging, prior positive detection, or regulatory concern.
Assessment Scope
A rigorous nitrosamine risk assessment covers all potential formation and contamination pathways across the entire product lifecycle.
API Risk Evaluation
Assessment of API molecular structure for secondary/tertiary amines and susceptibility to nitrosamine formation
Excipient Nitrite Risk
Review of excipient nitrite and nitrate content, supplier variability, and interaction potential with API
Primary Packaging Risk
Analysis of packaging materials for nitrosamine migration and chemical interactions during storage
Manufacturing Process Risk
Evaluation of process steps, equipment, reagents, and conditions that may contribute to nitrosamine formation
Storage & Degradation Risk
Assessment of stability conditions, temperature, humidity, and photolytic or hydrolytic degradation pathways
Analytical Testing Strategy
Determination of appropriate analytical methods, limits, and testing requirements based on risk category
Deliverables
Every engagement produces regulatory-ready documentation aligned with ICH M7, WHO, and MENA/GCC authority expectations.
Risk assessment report aligned with ICH M7 and regulatory requirements
Risk categorization (Low / Medium / High) with supporting rationale
Data gap list identifying missing information required for compliance
Testing recommendation specifying methods, limits, and timelines
Mitigation plan with prioritized action items for risk reduction
Regulatory-ready documentation suitable for CTD Module 3 inclusion
Technical Authority
KH Scientific Solutions
Pharmaceutical Technical Consulting | MENA & GCC
KH Scientific Solutions provides practical regulatory and technical support for pharmaceutical companies navigating nitrosamine compliance requirements. Our team combines deep R&D expertise with hands-on regulatory experience to deliver actionable risk assessments that meet health authority expectations across MENA and GCC markets.
Start Your Nitrosamine Risk Assessment
Submit your inquiry and a KH Scientific Solutions consultant will review your product situation and recommend the appropriate assessment scope.
Frequently Asked Questions
Which regulatory guidelines apply to nitrosamine risk assessment?
The primary guideline is ICH M7 (Assessment and Control of DNA Reactive Impurities in Pharmaceuticals). WHO, EMA, FDA, SFDA, and EDA have all issued specific guidance documents based on ICH M7. EFPIA has also published a practical workflow for conducting assessments. Requirements vary by authority, so the assessment must be tailored to target markets.
Does nitrosamine risk assessment apply to all drug products?
Yes. All chemical drug products require nitrosamine risk assessment as part of their quality dossier. The scope and depth of assessment varies based on product type, API chemistry, excipients, and manufacturing process. Biological products may be excluded from some requirements but still need evaluation.
What is the acceptable intake limit for nitrosamines?
Acceptable intake (AI) limits vary by nitrosamine compound. For example, NDMA limit is 96 ng/day and NDEA is 26.5 ng/day based on ICH M7 calculations. Products above these limits require mitigation actions and regulatory notification. Product-specific limits can also be derived using the TTC (threshold of toxicological concern) approach.
How long does a nitrosamine risk assessment take?
A standard nitrosamine risk assessment takes 4–8 weeks depending on product complexity, data availability, and the number of risk factors to evaluate. Urgent regulatory deadlines can be accommodated. If significant data gaps require new testing, timelines extend accordingly.
Can KH Scientific Solutions prepare the regulatory documentation?
Yes. All our nitrosamine risk assessment deliverables are prepared in regulatory-ready format suitable for inclusion in CTD Module 3. We also support deficiency response if your existing assessment is challenged by a health authority.
